Release Date: November 25, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Did you say potential in-licensing of one asset in '25 and one in '26? A: Yes, that's our plan. We have a number of assets that we're already looking at. Business development doesn't always go exactly according to plan, but overall, that's our plan. - Philip Serlin, CEO
Q: How do you mix the pancreatic program with the potential for motixafortide in additional solid tumor indications, and can you discuss the level of maturity of these discussions? A: We view PDAC as a prototype for other solid tumors. We are not investing more in PDAC currently, as we have ongoing collaborations at low cost. We hope for interim data in 2026, which could lead to business development discussions. - Philip Serlin, CEO
Q: Regarding the Ayrmid APHEXDA sale, do they have any potential option on the solid tumor program? A: They do not have any option on the solid tumor program. - Philip Serlin, CEO
Q: Can you provide some color on where you view the company's core competencies as we wait to hear more about the addition of potential assets to your pipeline? A: We are returning to our roots as an Israeli-based development company with a highly experienced team. We have capabilities in regulatory affairs, CMC, quality assurance, clinical operations, and preclinical development. We also have cash flows from partnerships and ongoing trials in PDAC at minimal cost. - Philip Serlin, CEO
Q: Looking at the 2025 expenses, you indicated a 70% reduction in spend next year. Is it fair to assume this is mostly from sales and marketing expenses? A: It's more than just sales and marketing. We expect a decrease in G&A expenses as well. We aim to be lean and efficient, focusing development in Israel, which is a low-cost environment. - Philip Serlin, CEO
Q: On the R&D side, should we think of that continuing at the same level, and what are those obligations? A: We have some post-marketing commitments with the FDA and PDAC commitments, but these are minimal. Most of our R&D spend will be on new projects as we bring them in. - Philip Serlin, CEO
Q: As we look at potentially a pivotal trial in PDAC, would that be taken over by partners? A: Yes, we believe partnering would be the best path forward for a trial of this size in solid tumors, especially with robust Phase IIb data. - Philip Serlin, CEO
Q: On China, when would you expect the first revenues to show up from that region? A: It's hard to say, but we hope for revenues in 2025. We don't have full control over Gloria's actions, but we are in regular contact with them. - Philip Serlin, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.